Limits...
Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis.

Liao KL, Bai XF, Friedman A - PLoS ONE (2014)

Bottom Line: In the present paper we develop a mathematical model based on these experimental results.We include in the model an anti-IL-35 drug as treatment.We find that with a fixed total amount of drug, continuous injection has better efficacy than intermittent injections in reducing the tumor load while the treatment is ongoing.

View Article: PubMed Central - PubMed

Affiliation: Mathematical Biosciences Institute, The Ohio State University, Columbus, Ohio, United States of America.

ABSTRACT
Interleukin-35 (IL-35), a cytokine from the Interleukin-12 cytokine family, has been considered as an anti-inflammatory cytokine which promotes tumor progression and tumor immune evasion. It has also been demonstrated that IL-35 is secreted by regulatory T cells. Recent mouse experiments have shown that IL-35 produced by cancer cells promotes tumor growth via enhancing myeloid cell accumulation and angiogenesis, and reducing the infiltration of activated CD8[Formula: see text] T cells into tumor microenvironment. In the present paper we develop a mathematical model based on these experimental results. We include in the model an anti-IL-35 drug as treatment. The extended model (with drug) is used to design protocols of anti-IL-35 injections for treatment of cancer. We find that with a fixed total amount of drug, continuous injection has better efficacy than intermittent injections in reducing the tumor load while the treatment is ongoing. We also find that the percentage of tumor reduction under anti-IL-35 treatment improves when the production of IL-35 by cancer is increased.

Show MeSH

Related in: MedlinePlus

Sensitivity analysis.PRCC values at the second months for the parameters in Table 14 with p-value smaller than .
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4214702&req=5

pone-0110126-g005: Sensitivity analysis.PRCC values at the second months for the parameters in Table 14 with p-value smaller than .

Mentions: Since we focus on how anti-IL-35 drug inhibits tumor growth, we calculate the partial rank correlation coefficients (PRCC) and p-value, corresponding to the ratio for months, where accounts for continuous treatment and accounts for of no drug; is a measure of the (relative) efficacy of the drug. In this analysis, all the parameters are chosen in the range from half to twofold of their baseline, except which is chosen from to . Table 14 lists the PRCC and their p-values. Figure 5 plots the PRCC of the parameters with p-values smaller than . A negative PRCC (i.e. negative correlation) with p-value smaller than means that increasing this parameter value will decrease the value of and hence increase the (relative) efficacy of the drug. A positive PRCC with p-value smaller than has the opposite meaning, that is, it will decrease the efficacy of the drug.


Mathematical modeling of Interleukin-35 promoting tumor growth and angiogenesis.

Liao KL, Bai XF, Friedman A - PLoS ONE (2014)

Sensitivity analysis.PRCC values at the second months for the parameters in Table 14 with p-value smaller than .
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4214702&req=5

pone-0110126-g005: Sensitivity analysis.PRCC values at the second months for the parameters in Table 14 with p-value smaller than .
Mentions: Since we focus on how anti-IL-35 drug inhibits tumor growth, we calculate the partial rank correlation coefficients (PRCC) and p-value, corresponding to the ratio for months, where accounts for continuous treatment and accounts for of no drug; is a measure of the (relative) efficacy of the drug. In this analysis, all the parameters are chosen in the range from half to twofold of their baseline, except which is chosen from to . Table 14 lists the PRCC and their p-values. Figure 5 plots the PRCC of the parameters with p-values smaller than . A negative PRCC (i.e. negative correlation) with p-value smaller than means that increasing this parameter value will decrease the value of and hence increase the (relative) efficacy of the drug. A positive PRCC with p-value smaller than has the opposite meaning, that is, it will decrease the efficacy of the drug.

Bottom Line: In the present paper we develop a mathematical model based on these experimental results.We include in the model an anti-IL-35 drug as treatment.We find that with a fixed total amount of drug, continuous injection has better efficacy than intermittent injections in reducing the tumor load while the treatment is ongoing.

View Article: PubMed Central - PubMed

Affiliation: Mathematical Biosciences Institute, The Ohio State University, Columbus, Ohio, United States of America.

ABSTRACT
Interleukin-35 (IL-35), a cytokine from the Interleukin-12 cytokine family, has been considered as an anti-inflammatory cytokine which promotes tumor progression and tumor immune evasion. It has also been demonstrated that IL-35 is secreted by regulatory T cells. Recent mouse experiments have shown that IL-35 produced by cancer cells promotes tumor growth via enhancing myeloid cell accumulation and angiogenesis, and reducing the infiltration of activated CD8[Formula: see text] T cells into tumor microenvironment. In the present paper we develop a mathematical model based on these experimental results. We include in the model an anti-IL-35 drug as treatment. The extended model (with drug) is used to design protocols of anti-IL-35 injections for treatment of cancer. We find that with a fixed total amount of drug, continuous injection has better efficacy than intermittent injections in reducing the tumor load while the treatment is ongoing. We also find that the percentage of tumor reduction under anti-IL-35 treatment improves when the production of IL-35 by cancer is increased.

Show MeSH
Related in: MedlinePlus